Skip to content

Scholar Rock SRRK Operating lease liabilities

Operating lease liabilities at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Arrowhead Research logo
Arrowhead ResearchARWR
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Viking Therapeutics logo
Viking TherapeuticsVKTX

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$6.14B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's operating lease liabilities?
Scholar Rock (SRRK) reported operating lease liabilities of -$1.44M in Q1 2026.
How has Scholar Rock's operating lease liabilities changed year-over-year?
Scholar Rock's operating lease liabilities increased by 8.6% year-over-year, from -$1.58M to -$1.44M.
What is the long-term trend for Scholar Rock's operating lease liabilities?
Over 4 years (2021 to 2025), Scholar Rock's operating lease liabilities has grown at a 1.7% compound annual growth rate (CAGR), from -$5.4M to -$5.77M.